Clinical study of duloxetine in treatment of persistent somatoform pain disorder

AIM:To explore the therapeutic effect and safety of duloxetine in treating patients with persistent somatoform pain disorder(PSPD).METHODS:A randomized,double-blind,placebo-controlled and follow-up study were taken.70 PSPD patients were involved in our study,randomly divided into 2 groups separately using the duloxetine and the placebo.The patients were evaluated with simplified mcGill score chart for paining(SFMPQ),hamilton depression scale(HAMD),hamilton anxiety scale(HAMA) and treatment emergent symptom scale(TESS) before and after treatment,(1,2,4 and 6weeks),respectively.Those patients with the reducing score rate of SF-MPQ in present rating index(PRI)≥50%were involved in the follow-up study and evaluated with SF-MPQ,HAMD,HAMA and TESS after 3,6 months.RESULTS:All the scores of SF-VIPQ,HAMD and HAMA 1week after treatment in both groups were significantly different with those scores before treatment(P 0.05).The scores of present pain intensity(PPI)after one week treatment,and the scores of SFMPQ,HAMD and HAMA after 2,4 and 6 weeks of the treatment were significantly different between the two groups(P 0.05).The total side effects in treatment group were higher than that in the control group(P 0.05).However,there was no significant difference in the incidence of single side effects.There were 17 patients with the reducing score rate of PRI-50%who were involved in the follow-up study.Comparing to 6 weeks after treatment,no significant difference were observed at 3and 6months after treatment(P 0.05).CONCLUSION:Duloxetine is effective and safety treatment of patient with persistent somatoform pain disorder.